title: [Pyoderma gangrenosum: case series].
abstract: Pyoderma Gangrenosum (PG) is a rare ulcerative cutaneous condition with distinctive characteristics, and the aetiology is not clear yet. PG is commonly associated with inflammatory bowel disease (Ulcerative Colitis and Crohn's disease). The features of PG are not specific histopathologically and for this reason diagnosis is based on clinical feature. There is no single successful treatment for PG. In fact certain type of lesions respond more readily to some therapies than others. Local treatments (advanced wound care, local corticosteroids, local immunomodulator agents) may be sufficient for some clinical features, while others may be required systemic therapy (corticosteroids, immunosuppressive therapy, intravenous immune globulins, TNF-alpha blocking agents). We present four cases of PG associated with inflammatory bowel diseases treated with different therapeutic approaches.
authors.affiliation: Dipartimento di Dermatologia Venereologia e Chirurgia Plastica Ricostruttiva, Università di Roma La Sapienza, Roma, Italia. antoniorichetta@hotmail.com
authors.forename: A G
authors.initials: AG
authors.lastname: Richetta
authors.forename: E
authors.initials: E
authors.lastname: Maiani
authors.forename: V
authors.initials: V
authors.lastname: Carboni
authors.forename: V
authors.initials: V
authors.lastname: Carlomagno
authors.forename: M
authors.initials: M
authors.lastname: Cimillo
authors.forename: C
authors.initials: C
authors.lastname: Mattozzi
authors.forename: S
authors.initials: S
authors.lastname: Calvieri
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D003879:Dermatologic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000150:complications; D008297:Male; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000305:Adrenal Cortex Hormones; D003879:Dermatologic Agents; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha